Five things to know:
1. Stryker agreed to purchase issued and outstanding ordinary shares of Wright Medical for $30.75 per share, a total equity value of around $4 billion. Including convertible notes, the enterprise value of the transaction is $5.4 billion.
2. Wright Medical is focused on extremities and biologics, and will complement Stryker’s trauma and extremities business.
3. Some analysts anticipate there could be antitrust issues with the planned transaction, especially as Wright Medical’s STAR ankle business has 70 percent of the total ankle replacement market.
4. The board of directors from both companies have approved the transaction and plan to close during the second half of 2020.
5. Stryker doesn’t anticipate the acquisition will affect net earnings per diluted share and adjusted net earnings per diluted share this year. The company has not updated its expected adjusted earnings per share for the full year.
More articles on orthopedic devices:
Smith+Nephew Q3 revenue up 6.5% to $1.2B: 5 key notes
Alphatec posts Q3 loss—6 insights
Conformis revenue down 40% in Q3, net loss hits $8.7M: 5 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.